Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV IgG + Vyjuvek in Dystrophic Epidermolysis Bullosa
NCT06834035Phase 2Recruiting
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of IgPro10 in Recessive Dystrophic Epidermolysis Bullosa (RDEB), epidermolysis bullosa acquisita (EBA). Started Aug 2025; status: recruiting.
02
Drugs
IgPro10
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)epidermolysis bullosa acquisita (EBA)
Beyond the preview
Go deeper on NCT06834035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834035.